Uncategorized

In the scorching summer, experts gathered in the cool city of Harbin for the 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. Held from July 26 to 28, 2024, this grand event brought together renowned experts and scholars from home and abroad to present on leukemia, lymphoma, and myeloma, sharing research findings and practical experiences. "Oncology Frontier - Hematology Frontier" had the honor of interviewing Dr. Zhixiang Shen, chairman of this conference and a professor at Ruijin Hospital, Shanghai JiaoTong University School of Medicine. He discussed the highlights of the conference, the current status of indolent lymphoma diagnosis and treatment, the concept of chronic disease management in hematological oncology, and future trends in the field.

The CHRYSALIS-2 study (NCT04077463) Cohort C investigated the combination of amivantamab and lazertinib for the treatment of patients with atypical EGFR-mutant non-small cell lung cancer (NSCLC). The study enrolled patients with various EGFR mutations who were either treatment-naive or had received limited prior treatment. The results demonstrated that the amivantamab+lazertinib combination showed promising antitumor activity, particularly in treatment-naive patients. The overall response rate was 51% (95% CI: 41%-61%), with a response rate of 55% (95% CI: 40%-69%) in treatment-naive patients. In this subgroup, the median progression-free survival (PFS) for the amivantamab+lazertinib combination was 19.5 months (95% CI: 11.0-not estimable). Overall, these findings suggest that amivantamab+lazertinib has potential as a new treatment option for patients with advanced NSCLC carrying atypical EGFR mutations. Principal investigator Dr. Byoung Chul Cho from Yonsei Cancer Center in Korea discussed the results of this study in an international media interview.

Upper tract urothelial carcinoma (UTUC), which includes renal pelvis cancer and ureteral cancer, is classified alongside bladder cancer as a type of urothelial carcinoma. However, the overall incidence of UTUC is relatively low, and there are still some contentious issues in its diagnosis and treatment strategies. At the recent 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association held in Xi'an, Dr. Hailiang Zhang from Fudan University Shanghai Cancer Center delivered an insightful lecture titled "Systemic Treatment of UTUC: Challenges, Breakthroughs, and Future Directions." Following the conference, Urology Frontier invited Professor Zhang to discuss the characteristics of UTUC patients in China, perioperative treatment strategies, and the progress of his research team.

From July 5th to 7th, 2024, the Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the wake of ASCO's profound impact, BOC/BOA gathered cutting-edge advancements from home and abroad, showcasing China's innovative capabilities. With a special focus on hematologic malignancies and oncology innovation, the event resonated with global progress. "Oncology Frontier - Hematology Frontier" interviewed one of CSCO's founders, Professor Jun Ma, Director of the Harbin Institute of Hematology and Oncology, to highlight the significance of BOC/BOA.

Patients with AIDS have a significantly higher risk of developing non-Hodgkin lymphoma (NHL) compared to the general population. To promote a deeper understanding and standardized treatment of AIDS-related lymphoma (ARL), a special session titled "ARL: EHA-ESMO Clinical Practice Guidelines" was held at the recent 29th Annual Meeting of the European Hematology Association (EHA 2024). Oncology Frontier - Hematology Frontier interviewed the session chair, Dr. Igor Aurer from the University Hospital Centre Zagreb and Medical School, University of Zagreb, Zagreb, Croatia. He discussed the pathogenesis of ARL, treatment challenges, key updates to the guidelines, practical clinical advice, and his outlook for next year's EHA meeting and advancements in hematology.

At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Professor Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating thrombocytopenia following cord blood transplantation (UCBT) was selected for oral presentation (OC33.3), with Dr. Huang delivering the report. This study not only showcases the exceptional capabilities of Chinese research teams in hematology but also contributes valuable insights to the global hematology community. "Oncology Frontier - Hematology Frontier" had an exclusive interview with Dr. Aijie Huang to delve deeper into the research and discuss future plans in the field of UCBT.

From July 12th to 14th, the 2024 CACA Integrated Breast Cancer Conference and The 8th Yunling Breast Cancer Summit Forum were held in Kunming, Yunnan. "Oncology Frontier" invited Professor Guojun Zhang, the chairman of both conferences and the president of Yunnan Cancer Hospital, to introduce the conference highlights, the hot directions of translational medicine research in breast cancer, and the achievements of Yunnan Cancer Hospital in breast cancer discipline construction. He also shared his outlook on the application prospects of artificial intelligence in breast cancer.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA, showcasing numerous cutting-edge research findings that will further advance the diagnosis and treatment practices in the field of urological tumors. Among them, a multicenter Phase II clinical study conducted in China, led by Peking University Cancer Hospital, on disitamab vedotin (RC48) combined with toripalimab for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) with HER2 expression has been included (Abstract No. 4568). "Oncology Fron

Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, Professor Chun Wang’s team at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital successfully applied a new approach: post-allo-HSCT infusion of donor-derived CD7 CAR-T cells to treat a case of refractory T-ALL/LBL. This study, published in Frontiers in Immunology, offers new strategies for treating R/R T-ALL/LBL patients. We conducted an exclusive interview with the study's first author, Professor Ying Jiang, to provide a deeper understanding of this research.

ACLF Monthly Review" is a special academic review column on ACLF invited by the editorial department of Hepatology Digest, created by the Chinese Acute-on-Chronic Liver Failure Consortium (Ch-CLIF-C). Each month, this column focuses on a specific area related to ACLF, aiming to popularize the concept and significance of ACLF and help readers quickly understand developments in the field. This column is intended to benefit both liver disease experts and researchers who need to understand current hotspots in the field, as well as frontline clinical practitioners who require practical knowledge.